Table 3 List of clinical trials of nanotechnology-based applications in cancer diagnosis
From: Nanotechnology in cancer diagnosis: progress, challenges and opportunities
Title | Disease | Nanotechnology | Purpose | Phase | NCT number |
|---|---|---|---|---|---|
Carbon Nanoparticles as lymph node tracer in rectal cancer after neoadjuvant radiochemotherapy | Rectal cancer | CNP (carbon nanoparticle) | Lymph node tracer | Not applicable | NCT03550001 |
Ferumoxytol-iron oxide nanoparticle magnetic resonance dynamic contrast-enhanced MRI | Head and neck cancer | Iron oxide nanoparticle | Imaging | Early Phase 1 | NCT01895829 |
Application of carbon nanoparticles in laparoscopic colorectal surgery | Colorectal tumor | CNP | Tumor localization and lymph node mapping | Not applicable | NCT03350945 |
Sentinel lymph node mapping in endometrial cancer | Endometrial neoplasms | CNP | Lymph node mapping | Not applicable | NCT03778255 |
Sentinel lymph node mapping in cervical cancer | Uterine cervical neoplasms | CNP | Lymph node mapping | Not applicable | NCT03778268 |
Targeted silica nanoparticles for real-time image-guided intraoperative mapping of nodal metastases | Head and neck cancer Melanoma Breast cancer Colorectal cancer | Fluorescent cRGDY-PEG-Cy5.5-C dots | Imaging/Localization | Phase 1/Phase 2 | NCT02106598 |
Nanochip technology in monitoring treatment response and detecting relapse in participants with diffuse large B-cell lymphoma | Lymphoma | Immuno-tethered lipoplex nanoparticle | Monitoring/detection | Not applicable | NCT03656835 |
Diagnosis of gastric lesions with Na-nose | Stomach diseases/Gastric cancer | Nanosensors | Diagnosis | Â | NCT01420588 |
PET imaging of patients with melanoma and malignant brain tumors using a 124I-labeled cRGDY silica nanomolecular particle tracer: a microdosing study | Metastatic melanoma/malignant brain tumors | 124I-cRGDY-PEG-dots | Localization | Not applicable | NCT01266096 |
Imaging of patients with malignant brain tumors using 89Zr-cRGDY ultrasmall silica particle tracers: a phase 1 microdosing study | Brain cancer | 89Zr-DFO-cRGDY-PEG-Cy5-C' dots | PET imaging | Phase 1 | NCT03465618 |